KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER Jun 27, 2024 08:15AM
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement May 23, 2024 02:41PM
Kazia Therapeutics (KZIA) Reports Successful Stage 1 Completion Of The EVT801 Phase 1 Clinical Trial In Advanced Cancer Patients May 1, 2024 08:46AM
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS May 1, 2024 08:45AM
Kazia Therapeutics (KZIA) Licenses Paxalisib to Sovargen Mar 21, 2024 08:52AM
View Older Stories

Mar 21, 2024 08:52AM Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Mar 13, 2024 08:00AM Kazia announces presentation of new data at AACR Annual Meeting
Feb 21, 2024 07:33AM Kazia Therapeutics (KZIA) Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
Feb 21, 2024 07:30AM Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
Jan 18, 2024 07:31AM Kazia Therapeutics (KZIA) Announces Board Appointments
Jan 18, 2024 07:30AM KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
Dec 5, 2023 06:02PM Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
Dec 1, 2023 08:01AM Kazia Therapeutics (KZIA) to sell 4.44M shares at $0.45/ADS in direct offering
Dec 1, 2023 08:00AM Kazia Therapeutics Announces $2 Million Registered Direct Offering
Nov 29, 2023 07:01AM KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
Nov 21, 2023 07:30AM KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
Nov 20, 2023 04:31PM Kazia Therapeutics (KZIA) Receives Nasdaq Non-compliance Notice
Nov 20, 2023 04:30PM KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
Nov 15, 2023 08:30AM KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
Nov 10, 2023 07:01AM KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA
Nov 1, 2023 07:03AM Kazia Therapeutics (KZIA) Issues Prelim Update from Phase 2 Trial of paxalisib
Nov 1, 2023 07:01AM KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA
Oct 23, 2023 07:01AM KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY
Oct 11, 2023 07:01AM Kazia announces voluntary delisting from ASX
Oct 5, 2023 07:01AM KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS
Sep 29, 2023 07:01AM KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
Jul 6, 2023 07:00AM Kazia Therapeutics (KZIA) Granted FDA Fast Track Designation for paxalisib
Jul 6, 2023 07:00AM KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
Jun 8, 2023 07:00AM KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
May 25, 2023 07:01AM KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT
Apr 14, 2023 07:02AM Kazia (KZIA) Regains Compliance With Nasdaq Minimum Bid Price Requirement
Apr 14, 2023 07:01AM KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Apr 4, 2023 07:00AM KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING
Dec 15, 2022 07:01AM KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING
Dec 12, 2022 07:01AM KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
Dec 1, 2022 07:01AM COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL
Nov 9, 2022 07:00AM KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
Oct 27, 2022 07:00AM KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA
Oct 6, 2022 08:00AM PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY
Sep 9, 2022 08:00AM KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE
Sep 8, 2022 08:30AM KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
Aug 5, 2022 08:42AM Kazia Therapeutics (KZIA) Reports Promising Interim Phase 1 Data of Paxalisib in Combination with Radiotherapy
Aug 5, 2022 08:40AM KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
Jul 12, 2022 08:16AM Kazia Therapeutics (KZIA) Launches New Scientific Advisory Board to Develop Therapies for Brain Cancer
Jul 12, 2022 08:15AM KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER
Jul 6, 2022 07:00AM US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Jun 17, 2022 08:01AM Kazia Therapeutics (KZIA) Granted Orphan Drug Designation to paxalisib
Jun 17, 2022 08:00AM US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Jun 13, 2022 07:00AM POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING
Jun 7, 2022 07:00AM PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT
Jun 3, 2022 07:03AM Kazia Therapeutics (KZIA) Reports Positive Final Data from Phase 2 Study of paxalisib
Jun 3, 2022 07:00AM KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
May 31, 2022 07:00AM GBM AGILE OPENS TO PAXALISIB IN EUROPE
May 23, 2022 08:30AM KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
Apr 29, 2022 11:00AM KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
View Older Stories